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Cumulating evidence has indicated NAD + deficiency as a common central 23 pathological factor of multiple diseases and aging. NAD + supplement is highly protective 24 in various disease and aging models, while two key questions remain unanswered: 1) 25
Does extracellular NAD + also produce its effects through its degradation product adenosine? 26 2) Does extracellular NAD + produce the protective effects by affecting cells under 27 pathological insults only, or by affecting both normal cell and cells under pathological 28 insults? Since extracellular NAD + can be degraded into adenosine, and endogenous 29 adenosine levels are in the nanomolar range under physiological conditions, extracellular 30 NAD + may produce its effects through its degradation into adenosine. In this study we 31 used BV2 microglia as a cellular model to test our hypothesis that NAD + treatment can 32 increase the intracellular adenylate pool under basal conditions through its extracellular 33 degradation into adenosine. Our study has shown that extracellular NAD + increases the 34 adenylate pool of BV2 microglia under basal conditions through its degradation into 35 adenosine that enters the cells through equilibrative nucleoside transporters. The 36 intracellular adenosine is converted to AMP by adenosine kinase, which increases 37 intracellular ATP by both activating AMPK and increasing ADP that drives mitochondrial 38 FoF1-ATP synthase. Collectively, our study has suggested that extracellular NAD + can 39 enhance defensive capacity of normal cells through a novel pathway, which includes 40 extracellular NAD + degradation into adenosine and the activities of adenosine kinase and 41 AMPK. Our findings have also suggested that NAD + administration in various disease 42 and aging models may significantly affect the microglia under basal conditions. 43
Introduction 46 NAD + plays critical roles in a number of biological functions including energy 47 metabolism, mitochondrial activity, DNA repair and cell death (Ying, 2008) . 48
Accumulating evidence has also suggested that there are significant decreases in the NAD + 49 levels in the models of aging and a number of diseases (Ying, 2008; Verdin, 2015; Zhang 50 and . Supplement with NAD + can produce profound beneficial effects in 51 animal models of aging and multiple diseases (Ying et Das et al., 2018), two key questions regarding the mechanisms underlying the protective 59 effects remains unanswered: 1) Does extracellular NAD + produce its effects through its 60 degradation products such as adenosine and nicotinamide? 2) Does extracellular NAD + 61 produce its protective effects by affecting cells under pathological insults only, or by 62 affecting both normal cells and cells under pathological insults? 63 Some previous findings have provided answers to the first question: Intranasal 64 administration of NAD + , but not nicotinamide, can profoundly decrease ischemic brain 65 injury and traumatic brain injury (Won et al., 2012) , which argues 66 against the possibility that extracellular NAD + produces its protective effects via nicotinamide -one of its degradation products. However, extracellular NAD + can also be 68 degraded into adenosine by multiple potential mechanisms (Moreschi et al., 2006; Klein et 69 al., 2009; Okuda et al., 2010b; Adriouch et al., 2012) . While it has been reported that the 70 radiolabeled adenosine moiety was observed in astrocytes within 10 mins of treatment of 71 the cells with radiolabeled NAD + (Okuda et al., 2010a) , there has been no report that 72 provides answers to the following question: Does extracellular NAD + produce its effects 73 through adenosine? Since it is established that adenosine can produce beneficial effects 74 under multiple pathological conditions (Ely and Berne, 1992; Zhang et al., 1993; Yap and 75 Lee, 2012), in our current study we used BV2 microglia as a cellular model to test our 76 hypothesis that extracellular NAD + produces its biological effects on cells via its 77 extracellular degradation into adenosine. 78
Regarding the second key question, there are studies suggesting that extracellular 79 NAD + produces its protective effects at least partially by directly entering cells to decrease 80 the damage of the cells under pathological insults: First, because such insults as oxidative 81 stress can lead to rapid decreases in the cytosolic NAD + concentrations by activating 82 However, there has been little information suggesting that the NAD + administration 98 may also decrease tissue damage by enhancing the defensive potential of normal cells that 99 have not been attacked at the time of exposures to the administered NAD + . Since the 100 intracellular NAD + concentrations in normal cells range from 1 mM -10 mM (Ying, 2008) , 101 it is unlikely that the NAD + administration, usually at the doses between 10 mg -20 mg/kg, 102 may produce NAD + concentrations in the blood which surpasses 1 mM. Therefore, it is 103 unlikely that extracellular NAD + may directly enter normal cells to produce its effects in 104 these models. However, since endogenous adenosine levels are in the nanomolar range 105 under physiological conditions (Latini and Pedata, 2001) , it is possible that the adenosine 106 that is generated from extracellular NAD + degradation may enter cells under basal 107 conditions through equilibrative nucleoside transporters (ENTs) to produce various 108 biological effects. 109
There have been few studies regarding the effects of NAD + treatment on cellular 110
properties under basal conditions. Our recent study has shown that NAD + treatment can induce significant increases in the intracellular ATP levels of BV2 microglia under basal 112 conditions, while the mechanisms underlying this effect of NAD + require future studies 113 . Because intracellular ADP and AMP are closely related with 114 intracellular ATP (Stryer, 1995) , we propose that NAD + treatment can significantly 115 increase the intracellular adenylate pool of BV2 microglia under basal conditions. 116
Increasing evidence has indicated that inflammation plays critical pathological roles in 
BV2 microglia under basal conditions 238
We determined the effects of NAD + on the intracellular adenylate levels of BV2 239 microglia, showing that treatment of 10, 100 and 500 μM NAD + can significantly increase 240 the intracellular levels of ATP, ADP and AMP of the cells (Figures 1A, 1B, 1C ). The 241 NAD + treatment also significantly increased the intracellular NAD + levels of the cells 242 ( Figure 1D) . Glycolysis and mitochondrial oxidative phosphorylation (OXPHOS) are major 248 pathways for ATP production, in which NAD + plays significant roles (Stryer, 1995) . Figure 1A) . We also 259 found that NAD + treatment was incapable of affecting the mitochondrial membrane 260 potential of the cells (Supplementary Figures 1B, 1C) . Moreover, neither the Complex I 261 inhibitor rotenone nor the Complex IV inhibitor sodium azide was capable of preventing 262 the NAD + -induced increases in the intracellular ATP levels ( Supplementary Figures 1D,  263   1E ). 264
We further found that SIRT1 inhibitor EX527 was incapable of affecting the 265 NAD + -induced increases in the intracellular ATP levels of the cells ( Supplementary Figure  266 2), thus arguing against the possibility that SIRT1 mediates the NAD + treatment-induced 267 increases in the adenylate pool in our study. 268 269
Contribution of adenosine transport to the NAD + -induced increases in the 270 intracellular adenylate levels of BV2 microglia under basal conditions 271
It has been reported that extracellular NAD + can be degraded into adenosine and the NAD + -induced increases in the intracellular ATP levels. We found that DPR blocked 281 the NAD + -induced increases in the intracellular levels of ATP, ADP and AMP (Figures 2A,  282 2B, 2C). 283
To exclude the possibility that NAD + produced the effects on the adenylate pool by 284 producing nicotinamide -another degradation product of NAD + , we determined if 285 nicotinamide may affect the intracellular ATP levels. Neither 10 nor 100 μM nicotinamide 286 affected the intracellular ATP levels, while 500 μM nicotinamide increased the intracellular 287 ATP levels by merely 10% (Supplementary Figure 3) . These observations argued against 288 the possibility that the nicotinamide moiety is responsible for the NAD + -induced increases in 289 the adenylate levels. 290 291
Extracellular adenosine is capable of increasing the intracellular adenylate pool of 292

BV2 microglia under basal conditions 293
To further test our proposal that the extracellular adenosine that is generated from 294 extracellular NAD + degradation can produce increased adenylate levels of BV2 microglia 295 under basal conditions, we determined the effects of 10, 100 and 500 μM adenosine 296 treatment on the intracellular ATP, ADP and AMP levels of BV2 microglia under basal 297 conditions. Our study showed that the adenosine at all of these concentrations was 298 capable of significantly increasing the intracellular adenylate levels of the cells ( Figures 3A,  299 3B, 3C). 300 301
Roles of adenosine kinase in the NAD + -induced increases in the adenylate levels of 302
BV2 microglia under basal conditions 303
Because endogenous adenosine levels are in the nanomolar range under normal 304 physiological conditions (Latini and Pedata, 2001) , it is possible that the concentrations of 305 the adenosine generated from the degradation of 10 -500 μM NAD + in our study may 306 surpass the intracellular adenosine concentrations, thus leading to entrance of the 307 extracellular adenosine into the cells. We found that treatment of BV2 microglia with 10, 308 100 and 500 μM NAD + significantly increased the intracellular adenosine levels (Figure  309 4A). 310
It has been reported that adenosine can be converted to AMP, which is mediated by 311 adenosine kinase (Miller et al., 1979) , leading to AMPK activation (da Silva et al., 2006) . 312 Therefore, we applied the adenosine kinase inhibitor 5-Iodotubercidin (5-ITU) to test our 313 hypothesis that the extracellular NAD + can produce increased intracellular AMP, ADP and 314 ATP by increasing intracellular adenosine that is converted to AMP by adenosine kinase. 315
We found that treatment of the cells with 5 μM 5-ITU virtually completely blocked the 316 NAD + -induced increases in the intracellular AMP, ADP and ATP levels of BV2 microglia 317 under basal conditions ( Figures 4B, 4C, 4D) . 318 319
Roles of AMPK in NAD + -induced increases in the adenylate levels of BV2 microglia 320 under basal conditions 321
Since AMPK is a crucial regulator of energy metabolism, which can be regulated by 322 such factors as AMP / ATP ratios (Hardie, 2015), we determined if AMPK is involved in 323 the NAD + -induced increases in the intracellular ATP levels of BV2 cells by assessing the 324 effects of NAD + treatment on AMPK phosphorylation. Both 100 and 500 μM NAD + led 325 to increased AMPK phosphorylation ( Figure 5A ). The AMPK phosphorylation induced 326 by NAD + was blocked by the adenosine kinase inhibitor 5-ITU ( Figure 5B ). The NAD + treatment did not affect the AMP / ATP ratios ( Figure 5C ), thus arguing against the 328 possibility that the NAD + treatment led to increased AMPK activity by increasing AMP / 329 ATP ratios. 330
We further determined the roles of AMPK in the NAD + -induced increases in the 331 intracellular ATP levels, showing that the AMPK inhibitor dorsomorphin blocked the 332 NAD + -induced increases in the ATP levels ( Figure 6A ). Moreover, treatment of the cells 333 with AMPK siRNA, which led to a significant decrease in the AMPK levels of the cells 334 ( Figure 6B ), also produced significant attenuation of the NAD + -induced increases in the 335 intracellular ATP levels ( Figure 6C ). 336
337
AMP treatment can increase both the intracellular adenylate levels and the AMPK 338 activity of BV2 microglia under basal conditions 339
Our study has indicated the extracellular NAD + can increase the intracellular AMP 340 levels by enhancing the levels of intracellular adenosine that can be converted by adenosine 341 kinase. We propose that the increased AMP may lead to increased levels of ATP and 342 ADP as well as increased AMPK activity. To test the validity of this proposal, we 343 determined the effects of AMP treatment, that has been reported to increase intracellular 344 AMP levels (Brenner and Gorin, 1978), on the intracellular levels of ATP and ADP as well 345 as the AMPK activity of BV2 microglia under basal conditions. Our study showed that 346 AMP treatment led to a significant increase in the intracellular AMP levels of the cells 347 ( Figure 7A) . The AMP treatment also produced significant increases in the intracellular 348 levels of ATP and ADP (Figures 7B, 7C) . Moreover, the AMP treatment significantly increased AMPK phosphorylation without affecting the intracellular AMP / ATP ratios of 350 the cells (Figures 7D, 7E) . ADP is one of the major substrates of mitochondrial FoF1-ATP synthase, which is an 355 important driving force for ATP synthesis (Stryer, 1995) . Therefore, we proposed that the 356 increased AMP-induced elevations of the intracellular ADP levels may enhance 357 mitochondrial FoF1-ATP synthase activity, leading to increased intracellular ATP levels of 358 BV2 microglia under basal conditions. We found that oilgomycin A, a selective inhibitor 359 of mitochondrial FoF1-ATP synthase, completely blocked the NAD + -induced increases in 360 the intracellular ATP levels (Figure 8) . 361 362 363
Discussion 364
The major findings of our current study includes: First, NAD + treatment can 365 significantly increase the intracellular levels of ATP, ADP and AMP of BV2 microglia 366 under basal conditions. Second, our study has provided evidence arguing against the 367 possibility that the NAD + treatment increased the intracellular adenylate pool by affecting 368 SIRT1, glycolytic rate or mitochondrial membrane potential of BV2 microglia under basal 369 conditions. Third, blockage of ENTs can prevent the NAD + -induced increases in the 370 intracellular adenylate pool of the cells. Fourth, NAD + treatment can significantly 371 increase the intracellular adenosine levels of the cells. Fifth, extracellular adenosine can 372 produce increased intracellular adenylate levels of the cells. Sixth, adenosine kinase 373 mediates the effects of NAD + on the intracellular adenylate pool of the cells. Seventh, 374 AMPK also mediates the NAD + -induced increases in the intracellular ATP. Eighth, 375 inhibition of mitochondrial FoF1-ATP synthase can block the NAD + -induced increases in 376 the intracellular ATP levels of the cells. 377
Previous studies have indicated that extracellular NAD + significantly decreases the 378 damage of the cells exposed to various pathological insults by such mechanisms as 379 improving glycolysis, preventing mitochondrial depolarization and activating SIRT1 (Ying and . However, our study has shown that the treatment of BV2 microglia with 382 0.01 -0.5 mM NAD + did not significantly increase the glycolytic rate and mitochondrial 383 membrane potential of BV2 microglia under basal conditions. Moreover, our study did 384 not show that SIRT1 inhibition can affect the NAD + -produced increases in the intracellular 385 adenylate pool of the cells under basal condition. Therefore, our study has indicated that 386 the mechanisms underlying the NAD + treatment-produced effects on the cells under 387 pathological insults are not applicable to the cells under basal conditions. These 388 observations are not surprising for the following reasons: The cytosolic NAD + 389 concentrations are normally in the ranges between 1 -10 mM (Ying, 2008) . Because 390 NAD + enters cells by gradient-driven transport (Alano et al., 2010), the NAD + at the 391 concentrations between 0.01 -0.5 mM, which was used in our study, should not be able to 392 enter the cells to influence the adenylate pools of BV2 microglia under basal conditions. 393
Our current study has indicated that extracellular NAD + produces its biological 394 effects on cells under basal conditions through mechanisms that are distinctly different 395 from the mechanisms found in the cells exposed to various pathological insults. Our study 396 has indicated that extracellular NAD + can produce significant biological effects on BV2 397 microglia under basal conditions through the following mechanism ( Fig. 9 ): Extracellular 398 NAD + is degraded into adenosine that enters the cells through ENTs, which is converted to 399 AMP by adenosine kinase. Increased AMP can lead to both increased AMPK activity and 400 increased intracellular ADP levels -a major driving force for mitochondrial FoF1-ATP 401 synthase, which jointly produce the increased intracellular ATP levels of BV2 cells under 402 basal conditions. 403
Although the NAD + at the concentrations between 0.01 -0.5 mM can not directly 404 enter cells to increase intracellular NAD + levels, we still found that the NAD + can 405 significantly increases the intracellular levels of NAD + and adenylate of BV2 microglia 406 through extracellular degradation into adenosine. Since intracellular adenosine levels are 407 normally in the nanomolar range (Latini and Pedata, 2001) , the extracellular 408 NAD + -generated adenosine can enter cells to increase intracellular adenosine levels thus 409 increasing the intracellular adenylate levels through the activities of adenosine kinase and 410 AMPK. In other words, the exceedingly low intracellular adenosine levels under normal 411 physiological conditions is an unique 'attractor' and base for the relatively low 412 concentrations of extracellular NAD + to produce its significant biological effects on cells. 413
While a previous study reported that extracellular NAD + can be degraded into adenosine, 414 which is transported into astrocytes through ENTs (Latini and Pedata, 2001) , to our 415 knowledge, our current study has provided the first direct evidence showing that 416 extracellular adenosine generated from extracellular NAD + degradation mediates the 417 biological effects of exogenous NAD + by adenosine kinase-and AMPK-mediated 418 pathways. 419
Our study has shown that relatively low concentrations of NAD + can increase both 420 extracellular and intracellular adenosine levels, the AMPK activity and intracellular 421 adenylate pools, all of these factors have been shown to enhance defensive potential of both 422 normal cells and stressed cells against toxic insults: AMPK activation has been reported to 
